Should you get a second Regenexx-SD procedure?

Summary

- When repeated at the right time, the 2nd SD procedure improved percentage outcome by 15-20 points.
- Most patients who repeated saw additional improvement.
- The patients who responded to a 2nd procedure achieved about 50% more improvement relative to the first procedure.

Data Collection

This data is based on our advanced treatment registry which collects outcome information as patients are treated. In particular, it doesn’t generalize to all knee stem cell procedures (only Regenexx-SD). Our biostatistician queried our database for Regenexx knee patients who had a second or subsequent procedure due to a partial response from their first procedure. In particular, most patients with an excellent initial response aren’t included in this data (i.e. they are less likely to repeat).

What percentage of patients saw any improvement with a second SD procedure?

What does this mean?

22 patients who had repeated an SD procedure from 2 months to 17 months after their first procedure for whom pre-second procedure scores were available are shown. Any improvement from baseline counted in the “Any Improvement” category. No improvement from baseline was noted as “W/O Improvement”.

Knee

When 2nd procedure repeated at 6-11 months after 1st procedure.

The mean change in responders with a second procedure was +19.2% with a relative change of 51.3% additional improvement when compared to the first procedure.

Details For Both Charts: The outcome measure used was a Likert % improvement self-reported by the patient on a -100% to +100 scale. This end point was queried at 3 months, 6 months, 12 months and annually. The patients received the Regenexx-SD same day procedure and this group is made up of the patients for which a pre-second procedure end-point was available. When the entire group of patients who repeated within 1 year is considered (n=21), the mean improvement was 50% to 59% (Std Dev 25-28, range 8-100). The median improvement for all patients was from 50% to 65%.

Caution! This is registry data, which is not the same as a drug company style controlled trial.